iRhythm (IRTC) vs Pulse Biosciences (PLSE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pulse Biosciences (PLSE) has outperformed iRhythm (IRTC) over the past year, gaining 150.7% versus a loss of 42.7%. Over five years, PLSE leads with a +130.9% price change compared with +41.9% for IRTC. Pulse Biosciences is the larger company by market cap ($3.72 billion vs $3.43 billion), about 1.1 times the size.
iRhythm converts more of its revenue into profit, with a net margin of -6.0% versus -20794.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRTC | PLSE |
|---|---|---|
| Share price | $103.99 | $52.14 |
| Market cap | $3.43B | $3.72B |
| 1-day change | +1.35% | +4.32% |
| YTD return | -42.18% | +264.02% |
| 1-year return | -42.68% | +150.65% |
| 5-year return | +41.93% | +130.85% |
| Forward P/E | 81.14 | — |
| EPS (TTM) | $-0.42 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $747.14M | $350.00K |
| Revenue growth (YoY) | +26.24% | — |
| Net income (latest FY) | $-44.55M | $-72.78M |
| Gross margin | 70.57% | -54.00% |
| Operating margin | -7.68% | -21982.57% |
| Net margin | -5.96% | -20794.57% |
| 52-week high | $212.00 | $58.90 |
| 52-week low | $100.70 | $12.56 |
| Distance from 52-week high | -50.95% | -11.48% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.26% | +8.36% |
| Average volume | 567.98K | 502.81K |
| Shares outstanding | 32.96M | 71.32M |
| Employees | 2,400 | 116 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLSE has outperformed IRTC by 193.3 percentage points over the past year.
- iRhythm is more profitable, keeping -6.0 cents of every revenue dollar as net income versus -20794.6 cents for Pulse Biosciences.
About iRhythm
IRTC stock →iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Health Care · Medical/Dental Instruments · 2,400 employees
About Pulse Biosciences
PLSE stock →Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
Health Care · Medical/Dental Instruments · 116 employees
IRTC vs PLSE FAQ
Which is bigger, iRhythm or Pulse Biosciences?
Pulse Biosciences (PLSE) is larger, with a market capitalization of $3.72B compared with $3.43B for iRhythm (IRTC).
Which stock has performed better over the past year, IRTC or PLSE?
PLSE returned +150.65% over the past 12 months, compared with -42.68% for IRTC (price return, excluding dividends). Past performance does not predict future results.
Are iRhythm and Pulse Biosciences in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.